|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
|
ES2339196T3
(es)
*
|
1997-07-18 |
2010-05-17 |
Novo Nordisk Health Care Ag |
Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
|
|
US6747003B1
(en)
*
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7247708B2
(en)
*
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6693075B1
(en)
|
1997-10-23 |
2004-02-17 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6406488B1
(en)
|
1998-08-27 |
2002-06-18 |
Heartstent Corporation |
Healing transmyocardial implant
|
|
EP0987274A1
(en)
|
1998-09-15 |
2000-03-22 |
Hoechst Marion Roussel Deutschland GmbH |
Factor VIIa Inhibitors
|
|
EP1059302A1
(en)
|
1999-06-08 |
2000-12-13 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitors
|
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1095933A1
(en)
|
1999-10-30 |
2001-05-02 |
Aventis Pharma Deutschland GmbH |
Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
|
|
WO2001058935A2
(en)
*
|
2000-02-11 |
2001-08-16 |
Maxygen Aps |
FACTOR VII OR VIIa-LIKE MOLECULES
|
|
US6926898B2
(en)
*
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
EP1162194A1
(en)
|
2000-06-06 |
2001-12-12 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
|
|
AU2001269803A1
(en)
*
|
2000-06-20 |
2002-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
US7160540B2
(en)
*
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
|
PT1345900E
(pt)
|
2000-12-06 |
2007-03-30 |
Sanofi Aventis Deutschland |
Derivados amidina e guanidina como inibidores do factor xa
|
|
US6825323B2
(en)
*
|
2001-01-10 |
2004-11-30 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
|
|
ES2432967T3
(es)
*
|
2001-03-22 |
2013-12-05 |
Novo Nordisk Health Care Ag |
Derivados del Factor VII de coagulación
|
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
|
IL158615A0
(en)
*
|
2001-05-02 |
2004-05-12 |
Novo Nordisk As |
Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
|
|
EP1270551A1
(en)
|
2001-06-26 |
2003-01-02 |
Aventis Pharma Deutschland GmbH |
Urea derivatives with antiproteolytic activity
|
|
AU2002326135A1
(en)
*
|
2001-09-10 |
2003-03-24 |
Florence Medical Ltd. |
Individual ffr determination for lesions of a multi-lesioned blood vessel
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
EP2292273A3
(en)
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodeling and glycoconjugation of peptides
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP1443956A2
(en)
*
|
2001-11-02 |
2004-08-11 |
Novo Nordisk Health Care AG |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
PL370656A1
(en)
*
|
2001-12-21 |
2005-05-30 |
Novo Nordisk A/S |
Liquid composition of modified factor vii polypeptides
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
JP2005530683A
(ja)
*
|
2001-12-21 |
2005-10-13 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第ｖｉｉ因子ポリペプチドの液体組成物
|
|
DE60334983D1
(de)
*
|
2002-04-30 |
2010-12-30 |
Bayer Healthcare Llc |
Faktor vii oder faktor viia polypeptidvarianten
|
|
JP5184738B2
(ja)
*
|
2002-05-03 |
2013-04-17 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
修飾第ｖｉｉ因子の安定化された固体組成物
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
CN101912601B
(zh)
|
2002-06-21 |
2012-08-29 |
诺和诺德医疗保健公司 |
因子vii多肽的稳定化固体组合物
|
|
JP4472526B2
(ja)
*
|
2002-09-30 |
2010-06-02 |
バイエル ヘルスケア エルエルシー |
凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
|
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
|
US20040176704A1
(en)
*
|
2003-03-04 |
2004-09-09 |
Stevens Timothy A |
Collection device adapted to accept cartridge for point of care system
|
|
CA2518327A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
|
EP2085470B1
(en)
*
|
2003-03-20 |
2012-05-16 |
Bayer HealthCare LLC |
FVII or FVIIa variants
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
CA2522345A1
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US20040202726A1
(en)
*
|
2003-04-10 |
2004-10-14 |
Deshay Samuel L. |
Topical blood pressure composition
|
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
|
EP1479675A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Indazole-derivatives as factor Xa inhibitors
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
|
EP1479680A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
|
KR20060015574A
(ko)
*
|
2003-05-23 |
2006-02-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
용액 중 단백질 안정화
|
|
US7029675B1
(en)
*
|
2003-06-04 |
2006-04-18 |
Shu-Wha Lin |
Hepsin antagonist and methods of use
|
|
JP4915918B2
(ja)
*
|
2003-06-19 |
2012-04-11 |
バイエル ヘルスケア エルエルシー |
第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
|
|
ES2382157T3
(es)
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
|
JP5306597B2
(ja)
*
|
2003-07-01 |
2013-10-02 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
EP1656158B1
(en)
|
2003-08-14 |
2016-03-09 |
Novo Nordisk Health Care AG |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
EP2311437A1
(en)
*
|
2003-12-19 |
2011-04-20 |
Novo Nordisk Health Care AG |
Stabilised compositions of factor VII polypeptides
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
CN102718859A
(zh)
*
|
2004-09-29 |
2012-10-10 |
诺和诺德医疗保健公司 |
通过分级洗脱从阴离子交换材料中纯化批量凝血因子vii多肽
|
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
EP2144923B1
(en)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Methods of treatment using glycopegylated g-csf
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
|
EP2379096B1
(en)
|
2008-12-19 |
2019-10-30 |
Baxalta GmbH |
Tfpi inhibitors and methods of use
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
ES2983470T3
(es)
|
2010-03-19 |
2024-10-23 |
Takeda Pharmaceuticals Co |
Inhibidores del TFPI y métodos de uso
|
|
KR101294351B1
(ko)
*
|
2010-05-27 |
2013-08-07 |
동국대학교 산학협력단 |
뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
|
|
WO2013123457A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
BR112014022435B1
(pt)
|
2012-03-21 |
2023-02-14 |
Takeda Pharmaceutical Company Limited |
Inibidores de tfpi e métodos de uso
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EA201691111A1
(ru)
|
2014-01-10 |
2017-01-30 |
Байоджен Ма Инк. |
Химерные белки фактора viii и их применение
|
|
MX2018000869A
(es)
*
|
2015-07-22 |
2018-07-06 |
Iconic Therapeutics Inc |
Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
|
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
|
DK3402537T3
(da)
|
2016-01-15 |
2021-03-29 |
Rigshospitalet |
Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
|
|
WO2018091058A1
(en)
|
2016-11-17 |
2018-05-24 |
Rigshospitalet |
177-lu labeled active site inhibited factor vii
|
|
KR20190090827A
(ko)
|
2016-12-02 |
2019-08-02 |
바이오버라티브 테라퓨틱스 인크. |
키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
|
|
KR102914074B1
(ko)
|
2018-05-18 |
2026-01-16 |
바이오버라티브 테라퓨틱스 인크. |
A형 혈우병의 치료 방법
|